Richard Law
Stock Analyst at Goldman Sachs
(2.37)
# 2,532
Out of 4,911 analysts
64
Total ratings
37.93%
Success rate
4.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals | Maintains: Buy | $20 → $18 | $4.57 | +293.87% | 5 | May 14, 2025 | |
| SLN Silence Therapeutics | Maintains: Sell | $4 → $3 | $6.28 | -52.23% | 3 | May 9, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Neutral | $15 → $13 | $3.21 | +304.98% | 3 | May 9, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $36 → $31 | $23.22 | +33.51% | 3 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $31 → $27 | $17.49 | +54.37% | 3 | May 7, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $30 | $33.50 | -10.45% | 1 | Apr 8, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $82 → $73 | $55.03 | +32.65% | 3 | Feb 27, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $28 → $24 | $14.26 | +68.30% | 6 | Feb 13, 2025 | |
| MRUS Merus | Initiates: Buy | $73 | $65.69 | +11.13% | 1 | Nov 21, 2024 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Neutral | $11 | $5.71 | +92.64% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $31 | $11.13 | +178.53% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $20.95 | +124.34% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $66.06 | -4.63% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $45.85 | -19.30% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $12.78 | +494.68% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $3.26 | +329.45% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $7.89 | +673.13% | 4 | May 8, 2023 |
Olema Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $4.57
Upside: +293.87%
Silence Therapeutics
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $6.28
Upside: -52.23%
Rocket Pharmaceuticals
May 9, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $3.21
Upside: +304.98%
Celldex Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $36 → $31
Current: $23.22
Upside: +33.51%
Viridian Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $31 → $27
Current: $17.49
Upside: +54.37%
Viking Therapeutics
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $33.50
Upside: -10.45%
MoonLake Immunotherapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $82 → $73
Current: $55.03
Upside: +32.65%
Mineralys Therapeutics
Feb 13, 2025
Maintains: Buy
Price Target: $28 → $24
Current: $14.26
Upside: +68.30%
Merus
Nov 21, 2024
Initiates: Buy
Price Target: $73
Current: $65.69
Upside: +11.13%
Monte Rosa Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $5.71
Upside: +92.64%
Aug 11, 2023
Reiterates: Neutral
Price Target: $31
Current: $11.13
Upside: +178.53%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $20.95
Upside: +124.34%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $66.06
Upside: -4.63%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $45.85
Upside: -19.30%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $12.78
Upside: +494.68%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $3.26
Upside: +329.45%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $7.89
Upside: +673.13%